Clinical trial
Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast…
NCT00461344 · Sanofi, Industry · Terminated
Key facts
| NCT number | NCT00461344 |
|---|---|
| Title | Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer |
| Official title | A Multicenter, Open Label, Phase II Trial Evaluating Docetaxel + Anthracycline x 4 Cycles Followed by Docetaxel Single Agent x 4 Cycles as First-Line Therapy in Patients With Her2 Negative Locally Advanced or Metastatic Breast Cancer Who Have Relapsed ≥ 12 Months From Completion of… |
| Lead sponsor | Sanofi, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ductal Carcinoma |
| Intervention type | Drug |
| Interventions | Docetaxel, Doxorubicin |
| Enrollment | 20 |
| Start date | Jul 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | Apr 18, 2007 |
| Last update posted | Apr 3, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: